| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 08/26/2004 | WO2001051003A3 Use of lipid conjugates in the treatment of disease |
| 08/26/2004 | US20040167341 Pyrrolidines as dipeptidyl peptidase inhibitors |
| 08/26/2004 | US20040167337 Boron compounds such as R)-1-{(S)-2-[(S)-2-(biphenyl-3-ylamino)-(3-(3,4,5-trimethoxy-phenyl)-propionylamino]-3-methyl-butyrylamino}-3-methyl-butylboronic acid, used as antitumor or antiproliferative agents |
| 08/26/2004 | US20040167332 Boronic ester and acid compounds, synthesis and uses |
| 08/26/2004 | US20040167330 Suitable targeting moieties are monoclonal antibodies, their fragments and recombinant derivatives such as single chain antibodies, diabodies, triabodies, humanized, human or chimeric variants but also peptides, aptamers, spiegelmers, nucleotides, anti sense oligomers |
| 08/26/2004 | US20040167323 Novel chitosans |
| 08/26/2004 | US20040167224 Nitrogen containing heterocyclic compounds and medicines containing the same |
| 08/26/2004 | US20040167205 Method for preparing and using polyoxyethylated castor oil in pharmaceutical compositions |
| 08/26/2004 | US20040167187 Sulfhydantoins as phosphate isosteres |
| 08/26/2004 | US20040167180 Anticancer agents |
| 08/26/2004 | US20040167176 Tricyclic compounds useful as angiotensin II agonists |
| 08/26/2004 | US20040167174 Substituted acylhydroxamic acids and method of reducing TNFalpha levels |
| 08/26/2004 | US20040167160 Skin disorders; controlling cell differentiation; antidiabetic agents; cardiovascular disorders; anticancer agents; central nervous system disorders |
| 08/26/2004 | US20040167154 Urea substituted imidazoquinolines |
| 08/26/2004 | US20040167152 Mixture of a rapamycin compound with cosolvent and antioxidant |
| 08/26/2004 | US20040167141 Anticancer agents; antidiabetic agents; Alzheimer's disease |
| 08/26/2004 | US20040167137 Xanthine phosphodiesterase V inhibitors |
| 08/26/2004 | US20040167134 Combination comprising n-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent |
| 08/26/2004 | US20040167133 Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4,3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| 08/26/2004 | US20040167131 Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade |
| 08/26/2004 | US20040167105 Osteoporosis; anticancer agents; autoimmune disease |
| 08/26/2004 | US20040167104 26,27-Homologated-20-epi-2-alkylidene-19-nor-vitamin D compounds |
| 08/26/2004 | US20040167100 Illudin analogs useful as antitumor agents |
| 08/26/2004 | US20040167089 Immunostimulatory nucleic acid molecules |
| 08/26/2004 | US20040167081 Method for the prevention and treatment of cachexia and anorexia |
| 08/26/2004 | US20040167074 Therapeutic applications of mFLINT polypeptides |
| 08/26/2004 | US20040167065 human transferases and polynucleotides which identify and encode them; expression vectors, host cells, antibodies, agonists, and antagonists; diagnosing, treating, or preventing disorders associated with aberrant expression of the transferases |
| 08/26/2004 | US20040167061 Substantially homogeneous bio-affecting material having a pre-determined ratio of bioaffecting component to cell targeting component, the method for making such a material and the method of its use |
| 08/26/2004 | US20040167060 Inhibitor and stimulator of stem cell proliferation and uses thereof |
| 08/26/2004 | US20040166565 for treating diseases relating to angiogenesis; fusion protein possesses ribosome inactivating activity and ability to bind to cellular vascular endothelial growth factor (VEGF) receptors |
| 08/26/2004 | US20040166559 Vectors for gene therapy |
| 08/26/2004 | US20040166544 Antibodies to c-Met for the treatment of cancers |
| 08/26/2004 | US20040166543 Regulation of cell growth by MUC1 |
| 08/26/2004 | US20040166517 Diagnosing breast cancer via presence of sulphate transporter proteins; antitumor agents |
| 08/26/2004 | US20040166115 Complex of protein and hapten-enzyme ; tumor antigen |
| 08/26/2004 | US20040166105 Compositions and methods relating to breast specific genes and proteins |
| 08/26/2004 | US20040166103 Treatment of malignant tumor |
| 08/26/2004 | US20040166092 Use of viral vectors and charged molecules for gene therapy |
| 08/26/2004 | US20040166090 Antitumor agents; induction apoptosis |
| 08/26/2004 | US20040166059 conjugates of a residue of vitamin B12 and a residue of a peptide or an amino acid comprising a radionuclide that are useful to image tumors |
| 08/26/2004 | CA2520591A1 Improved heat shock protein-based vaccines and immunotherapies |
| 08/26/2004 | CA2516254A1 Tetracyclic pyrazole derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| 08/26/2004 | CA2516236A1 Antibodies to c-met for the treatment of cancers |
| 08/26/2004 | CA2515761A1 Use of artemisinin for treating tumors induced by oncogenic viruses and for treating viral infections |
| 08/26/2004 | CA2515728A1 Antiproliferative 2-(sulfo-phenyl)-aminothiazole derivatives |
| 08/26/2004 | CA2515658A1 Medicinal composition |
| 08/26/2004 | CA2515368A1 Regulation of food intake and glucose production by modulation of long-chain fatty acyl-coa levels in the hypothalamus |
| 08/26/2004 | CA2515115A1 Identification of cellular polypeptides differentially expressed by tumor cells |
| 08/26/2004 | CA2514382A1 Pyrazoles and methods of making and using the same |
| 08/26/2004 | CA2514231A1 Uses of anti-insulin-like growth factor i receptor antibodies |
| 08/26/2004 | CA2514105A1 Chemical derivatives binding very specifically with g-quadruplex dna structures and use thereof as a specific anti-cancer agent |
| 08/26/2004 | CA2513668A1 Dyrks as modifiers of the apc and axin pathways and methods of use |
| 08/26/2004 | CA2511623A1 Remedy for cancer |
| 08/25/2004 | EP1449920A1 Non-human transgenic mammals used as models for human pathologies originating from stem cells |
| 08/25/2004 | EP1449850A1 Human cdr-grafted antibodies and antibody fragments thereof |
| 08/25/2004 | EP1449834A2 Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas |
| 08/25/2004 | EP1449535A1 Compositions comprising fetal hemoglobin and bacterial endotoxin and optionally additional fetal liver components |
| 08/25/2004 | EP1449534A1 Matrix metalloprotease inhibitor |
| 08/25/2004 | EP1449529A1 Protein Kinase C Inhibitors |
| 08/25/2004 | EP1449528A1 Treatment of respiratory diseases |
| 08/25/2004 | EP1448986A2 Conformation-activity relationship of apoptosis-inducing phosphodiester oligonucleotides |
| 08/25/2004 | EP1448790A2 Methods and compositions for treating cancer |
| 08/25/2004 | EP1448787A2 Human monoclonal antibodies to dendritic cells |
| 08/25/2004 | EP1448780A2 Direct targeting binding proteins |
| 08/25/2004 | EP1448603A2 Fusion proteins containing tlp peptides |
| 08/25/2004 | EP1448602A2 Modified anti-tnf alpha antibody |
| 08/25/2004 | EP1448599A2 Inhibitors of the notch signalling pathway for use in the treatment of cancer |
| 08/25/2004 | EP1448592A1 Steroidal compounds for inhibiting steroid sulphatase |
| 08/25/2004 | EP1448591A1 17alpha-alkyl-17beta-oxy-estratrienes and intermediates for the production thereof, and use of said 17alpha-alkyl-17beta-oxy-estratrienes for producing medicaments and pharmaceutical preparations |
| 08/25/2004 | EP1448588A2 Psma antibodies and protein multimers |
| 08/25/2004 | EP1448586A2 Therapeutic methods for nucleic acid delivery vehicles |
| 08/25/2004 | EP1448564A2 Substituted indolizine-like compounds and methods of use |
| 08/25/2004 | EP1448556A1 Heteroaryl amines as glycogen synthase kinase 3beta inhibitors (gsk3 inhibitors) |
| 08/25/2004 | EP1448551A1 Processes for the preparation of substituted bicyclic derivatives for the treatment of abnormal cell growth |
| 08/25/2004 | EP1448550A1 Nitrogenous tetrahydropyridyl-alkyl-heterocycles with tnf activity |
| 08/25/2004 | EP1448545A1 Nf-kb inhibitors |
| 08/25/2004 | EP1448544A1 Substituted benzopyrans as selective estrogen receptor-beta agonists |
| 08/25/2004 | EP1448542A1 6-hydroxy isoflavones, derivatives and medicaments involving same |
| 08/25/2004 | EP1448535A1 Benzamide and heteroarylamide as p2x7 receptor antagonists |
| 08/25/2004 | EP1448531A1 3-cyanoquinolines as inhibitors of egf-r and her2 kinases |
| 08/25/2004 | EP1448523A1 Heterocyclic compounds and methods of use |
| 08/25/2004 | EP1448513A1 Biphenyl-derivatives as p38-kinase inhibitors |
| 08/25/2004 | EP1448508A1 Double esters |
| 08/25/2004 | EP1448504A2 Clusianon isomers and use thereof |
| 08/25/2004 | EP1448268A2 Use of an farnesyl protein transferase inhibitor in combination with other antineoplastic agents for the manufacture of a medicament against cancer |
| 08/25/2004 | EP1448237A1 Selective treatment of il-13 expressing tumors |
| 08/25/2004 | EP1448236A1 Inclusion complex of taxol with 2-hxdroxypropyl-beta-cyclodextrin |
| 08/25/2004 | EP1448232A1 Anti-proliferative composition |
| 08/25/2004 | EP1448231A1 Topical delivery of codrugs |
| 08/25/2004 | EP1448229A2 Pharmaceutical composition for inducing an immune response in a human or animal |
| 08/25/2004 | EP1448227A2 Use of t-cell immune response cdna 7 (tirc7) for modulation of angiogenesis and/or neovascularization |
| 08/25/2004 | EP1448224A2 Use of selectin-binding active ingredients for the treatment of inflammatory and tumoral diseases |
| 08/25/2004 | EP1448215A2 Use of laminarin in the treatment of cancer as well as bacterial, viral and fungal infections |
| 08/25/2004 | EP1448199A1 Benzimidazoles useful as protein kinase inhibitors |
| 08/25/2004 | EP1448195A1 N-adamantylmethyl derivates and intermediates as pharmaceutical compositions and processes for their preparation |
| 08/25/2004 | EP1448189A2 Use of bisindolmaleimide and gemcitabine for the treatment of cancer |
| 08/25/2004 | EP1448179A1 Substituted bicyclo 3.3.1 nonan-2,4,9-triones as pharmaceutical active ingredients |
| 08/25/2004 | EP1448171A2 Pharmaceutical formulation comprising more than 15% tamoxifen |
| 08/25/2004 | EP1448168A1 Pharmaceutical formulation comprising bicalutamide |
| 08/25/2004 | EP1448152A2 Methods and compositions for the treatment and diagnosis of pain disorders using 2047 |